Filing Details
- Accession Number:
- 0001628280-24-047142
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-12 16:11:32
- Reporting Period:
- 2024-11-08
- Accepted Time:
- 2024-11-12 16:11:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356576 | Supernus Pharmaceuticals Inc. | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1539937 | A. Jack Khattar | C/O Supernus Pharmaceuticals Inc. 9715 Key West Avenue Rockville MD 20850 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-08 | 125,000 | $9.13 | 1,051,172 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-08 | 125,000 | $36.29 | 926,172 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2024-11-08 | 125,000 | $0.00 | 125,000 | $9.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-03-03 | 2025-03-03 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,022,450 | Indirect | By the KBT Trust |
Footnotes
- The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.66. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The option vested in four equal installments beginning on March 3, 2016.
Billionaire Hedge Funds
